Geniouskin’s approach begins with a small patient biopsy, from which skin cells are isolated and expanded within a proprietary biomimetic matrix. As a fully autologous therapy, it eliminates rejection risk.

The engineered graft is then applied directly to the wound, where it integrates naturally to restore full-thickness, functional, and pigmented skin in a single intervention.

This process is reinforced by Process AI and Clinical AI, enabling standardized production, cost efficiency, and advanced clinical decision support.